<span item_type="fundamental" item_id="700fcfcf645f192a29842053a0814a22" counter_id="ST/US/DMAAR" env="prod"></span><span item_type="announcement" item_id="518297578643984385" env="prod"></span><p>每股收益：截至 2025 財年 Q1，公佈值為 0.05 美元。</p><p></p><h3>財務指標</h3><h4>淨收入</h4><ul><li>截至 2025 年 3 月 31 日的三個月淨收入為 1,254,543 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h4>運營成本</h4><ul><li>一般和行政成本為 330,925 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h4>現金流</h4><ul><li>運營活動現金流為-251,244 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>投資活動現金流為-231,150,000 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>融資活動現金流為 231,400,816 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h4>資產負債</h4><ul><li>截至 2025 年 3 月 31 日，總資產為 232,806,487 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>總負債為 7,247,369 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h4>獨特指標</h4><ul><li>信託賬户中的現金和投資為 232,735,468 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h3>未來展望和戰略</h3><ul><li>公司計劃在 15 個月內完成首次業務合併，若未能完成，時間可延長至最多 21 個月。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>公司將繼續在製藥行業尋找業務合併目標。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>公司計劃使用信託賬户中的資金進行業務合併，並可能使用股權或債務作為合併的對價。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul>

DRUGS MADE IN AMER ACQUISITION CORP COM USD0.0001 15/10/2029 (SUB/RIGHTS)｜10-Q：2025 財年 Q1 每股收益 0.05 美元